Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Peter M. Grob is active.

Publication


Featured researches published by Peter M. Grob.


Photochemistry and Photobiology | 1995

INACTIVATION OF CELL SURFACE RECEPTORS BY PHEOPHORBIDE a, A GREEN PIGMENT ISOLATED FROM Psychotria acuminata

Jan A. Glinski; Eva David; Thomas C. Warren; Gordon Hansen; Scott F. Leonard; Phillip Pitner; Susan Pav; Rosita Arvigo; Michael J. Balick; Eligio Panti; Peter M. Grob

Abstract— The inhibition of cytokine and monoclonal antibody binding to cell surfaces caused by an extract of Psychotria acuminata, a medicinal plant used in the traditional medicine of the people of Belize (Central America), was attributed to the presence of pheophorbide a and pyropheophorbide a Since the binding of tumor necrosis factor‐alpha, interleukin‐8, complement factor 5a as well as epidermal growth factor to target cells was dramatically reduced, the inhibition was not receptor or cytokine specific. In addition, the respective binding of radiolabeled monoclonal antibodies CL203 and R15.7 to the cell surface antigens intracellular cell adhesion molecule‐1 and lymphocyte function‐associated antigen‐1 ß‐chain was decreased by pretreatment of cells with pheophorbide a as well. In all cases, the inhibition by pheophorbides was dependent on the simultaneous presence of light, indicating causative involvement of a photodynamic process. These observations are not unique to pheophorbides and can be extended to porphyrins as well as to other photodynamic agents. Cytotoxicity resulting from photodynamic therapy (PDT) has been documented by many studies. Our investigations suggest that the inactivation of cell surface receptors contributes not only to the antitumor effect of PDT but also to the systemic immunosuppression, a serious side effect of PDT.


Journal of Chromatography A | 1994

High-performance liquid chromatography and photoaffinity crosslinking to explore the binding environment of nevirapine to reverse transcriptase of human immunodeficiency virus type-1

Deborah E.H. Palladino; Jerry L. Hopkins; Richard H. Ingraham; Thomas C. Warren; Suresh R. Kapadia; Glenn J. Van Moffaert; Peter M. Grob; James M. Stevenson; Kenneth A. Cohen

Nevirapine (BI-RG-587) is a potent inhibitor of the polymerase activity of reverse transcriptase of human immunodeficiency virus type-1. Nevirapine, as well as several other non-nucleoside compounds of various structural classes, bind strongly at a site which includes tyrosines 181 and 188 of the p66 subunit of reverse transcriptase. The chromatography which was utilized to explore this binding site is described. BI-RH-448 and BI-RJ-70, two tritiated photoaffinity azido analogues of nevirapine, are each crosslinked to reverse transcriptase. The use of several HPLC-based techniques employing different modes of detection makes it possible to demonstrate a dramatic difference between the two azido analogues in crosslinking behavior. In particular, by comparing HPLC tryptic peptide maps of the photoadducts formed between reverse transcriptase and each azido analogue, it can be shown that crosslinking with BI-RJ-70 but not with BI-RH-448 is more localized, stable, and hence exploitable for the identification of the specifically bonded amino acid residue(s). In addition, comparison of the tryptic maps also makes it feasible to assess which rings of the nevirapine structure are proximal or distal to amino acid side chains of reverse transcriptase. Finally, another feature of the HPLC peptide maps is the application of on-line detection by second order derivative UV absorbance spectroscopy to identify the crosslinked amino acid residue.


Protein Expression and Purification | 1992

Comparative purification of recombinant HIV-1 and HIV-2 reverse transcriptase: Preparation of heterodimeric enzyme devoid of unprocessed gene product

Thomas C. Warren; John Miglietta; Anthony Shrutkowski; Janice M. Rose; Sheri L. Rogers; Klaus Lubbej; Cheng K. Shih; Gary O. Caviness; Richard H. Ingraham; Deborah E.H. Palladino; Eva David; Grace C. Chow; Elizabeth B. Kopp; Kenneth A. Cohen; Jan A. Glinski; Peter R. Farina; Peter M. Grob

A procedure for producing and purifying recombinant HIV-1 and HIV-2 reverse transcriptase (RT) is described. These enzymes are produced by Escherichia coli-transformed with a plasmid containing the gene encoding for either the human immunodeficiency virus type 1 (HIV-1) or HIV-2 RT protein. Both proteins are partially processed by host cell proteases giving rise to a mixture of heterodimeric and nonheterodimeric products, which are subsequently resolved to near homogeneity by chromatography on phosphocellulose, Q-Sepharose, and hydrophobic interaction HPLC. Both HIV-1 (66/51 kDa) and HIV-2 (68/54 kDa) heterodimeric enzymes devoid of excess unprocessed (p66 or p68) precursors are isolated, enabling comparative enzymatic characterization of the fully active (and biologically relevant) heterodimeric forms. Homogenous HIV-1 and HIV-2 RT purified by this methodology exhibit near equivalent polymerase and RNase H activities.


Methods in Enzymology | 1981

[80] Separation and characterization of molecular components of human leukocyte interferon by concanavalin A-agarose affinity chromatography

Peter M. Grob; Kailash C. Chadha

Publisher Summary This chapter reveals that human leukocyte interferon (HLIF) is composed of several homologous proteins that are coded for by separate genes in the genome. HLIF can be resolved into two molecular weight components by sodium dodecyl sulfate (SDS)-disc gel electrophoresis and, in addition, has been shown to contain fibroblast-type interferon as a minor component. These three molecular components: (1) 21,000-dalton component (Le21), (2) 16,000-dalton component (Le16), and (3) a fibroblast- type minor component (“F” type) cannot be effectively resolved either by gel filtration or by SDS-disc gel electrophoresis. The chapter describes the efficient separation of these three molecular components, in a single step, by chromatography of HLIF on concanavalin Aagarose. NDV is routinely used as an interferon inducer and human serum is present throughout the production period. It is conceivable that the nature or extent of molecular heterogeneity will vary if these production conditions are changed.


Biochemistry | 1991

A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site.

Joe C. Wu; Thomas C. Warren; Julian Adams; John R. Proudfoot; Jerry W. Skiles; Palayakotai Raghavan; Clark Perry; Ian Potocki; Peter R. Farina; Peter M. Grob


Journal of Biological Chemistry | 1990

Characterization of a receptor for human monocyte-derived neutrophil chemotactic factor/interleukin-8.

Peter M. Grob; Eva David; Tbomas C. Warren; Rodney P. DeLeon; Peter R. Farina; Carol Ann Homon


AIDS Research and Human Retroviruses | 1992

Nonnucleoside Inhibitors of HIV-1 Reverse Transcriptase: Nevirapine as a Prototype Drug

Peter M. Grob; Joe C. Wu; Kenneth A. Cohen; Richard H. Ingraham; Cheng-Kon Shih; Karl D. Hargrave; Tari L. Mctague; Vincent J. Merluzzi


Journal of Medicinal Chemistry | 1997

Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity.

Edward S. Lazer; Clara K. Miao; Charles L. Cywin; Ronald John Sorcek; Hin-Chor Wong; Zhaoxing Meng; Ian Potocki; Maryann Hoermann; Roger J. Snow; Matt Aaron Tschantz; Terence A. Kelly; Daniel W. McNeil; Simon J. Coutts; Laurie Churchill; Anne G. Graham; Eva David; Peter M. Grob; Wolfhard Engel; Hans Meier; Gunter Trummlitz


Journal of Medicinal Chemistry | 1997

Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. 6. 2-indol-3-yl- and 2-azaindol-3-yl-dipyridodiazepinones

Terence A. Kelly; Daniel W. McNeil; Janice M. Rose; Eva David; Cheng-Kon Shih; Peter M. Grob


Nucleic Acids Research | 1991

Steady state kinetics and inhibition of HIV-1 reverse transcriptase by a non-nucleoside dipyridodiazepinone, BI-RG-587, using a heteropolymeric template

Elizabeth B. Kopp; John Miglietta; Anthony Shrutkowski; Cheng-Kon Shih; Peter M. Grob; Mark T. Skoog

Collaboration


Dive into the Peter M. Grob's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kailash C. Chadha

Roswell Park Cancer Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge